What is the difference between Mvasi and Avastin?
Mvasi is not interchangeable with Avastin. The prescriber must write a prescription specifically for Mvasi.
A biosimilar, according to the FDA, is a biological product that is highly similar to an FDA-approved biological product, known as a reference product (in this case Avastin), and has no clinically meaningful differences in terms of safety and effectiveness.
See Biosimilar and Interchangeable Biologics: More Treatment Choices
Mvasi has the same approved indications as Avastin, with the exception of hepatocellular carcinoma.
Mvasi was approved in 2017 as the first biosimilar to Avastin. A second Avastin biosimilar called Zirabev (bevacizumab-bvzr) was approved in 2019, and a third called Alymsys (bevacizumab-maly) was approved in 2022.
Related medical questions
- What are monoclonal antibodies?
- What are biosimilar drugs?
- What are anti-VEGF drugs (VEGF inhibitors)?
- What’s the difference between Eylea, Eylea HD, and Avastin?
- What biosimilars have been approved in the United States?
- What is a biologic drug?
- How long does it take for Keytruda to work?
- What is the difference between Opdivo and Keytruda?
- How long does it take for Lenvima to work?
- How effective is Lenvima?
- How does Nexavar work? Is it a chemo drug?
Related support groups
- Avastin (8 questions, 44 members)
- Bevacizumab (4 questions, 7 members)
- Mvasi (3 questions, 5 members)
- Renal Cell Carcinoma (28 questions, 102 members)
- Non-Small Cell Lung Cancer (50 questions, 70 members)
- Colorectal Cancer (15 questions, 50 members)
- Cervical Cancer (5 questions, 25 members)
- Glioblastoma Multiforme (1 questions, 26 members)